Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00758784 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00758784 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 38 participants.
The verdict
NCT00758784, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of an ophthalmic solution in dry eye disease.
Interventions
- DRUG bromfenac ophthalmic solution 0.06%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-08-13 |
| Est. Completion | 2009-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00758784
The ClinicalTrials.gov registry entry for NCT00758784 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bromfenac ophthalmic solution 0.06% is the first listed.
NCT00758784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00758784 about?
NCT00758784 is a clinical study titled "Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease". The purpose of this study is to investigate the safety and efficacy of an ophthalmic solution in dry eye disease.
What is the current status of trial NCT00758784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2008-08-13. Estimated completion is 2009-01-14.
What interventions are being tested in trial NCT00758784?
The interventions under investigation include: bromfenac ophthalmic solution 0.06% (DRUG).
Who is sponsoring clinical trial NCT00758784?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.